Supply chain manufacturing and tariffs, including: the Section 232 and Section 301 tariff investigations related to branded pharmaceuticals.
Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Pharmaceutical manufacturing.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.